Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Open accessThe DOI matches its Crossref record; 336 of the 336 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature myeloid cells with immunosuppressive effects, which undergo massive expansion during tumor progression. These cells not only support immune escape directly but also promote tumor invasion via various non-immunological activities. Besides, this group of cells are proved to impair the efficiency of current antitumor strategies such as chemotherapy, radiotherapy, and immunotherapy. Therefore, MDSCs are considered as potential therapeutic targets for cancer therapy. Treatment strategies targeting MDSCs have shown promising outcomes in both preclinical studies and clinical trials when administrated alone, or in combination with other anticancer therapies. In this review, we shed new light on recent advances in the biological characteristics and immunosuppressive functions of MDSCs. We also hope to propose an overview of current MDSCs-targeting therapies so as to provide new ideas for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–336 of 336
CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection
Wennerberg, E., Spada, S., Rudqvist, N.-P., Lhuillier, C., Gruber, S., Chen, Q., Zhang, F., Zhou, X. K., Gross, S. S., Formenti, S. C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0449 · Cited by 155
Sinha, P., Chornoguz, O., Clements, V. K., Artemenko, K. A., Zubarev, R. A., & Ostrand-Rosenberg, S. (2011) · Blood · doi:10.1182/blood-2010-11-321752 · Cited by 154
Bergenfelz, C., Larsson, A.-M., von Stedingk, K., Gruvberger-Saal, S., Aaltonen, K., Jansson, S., Jernström, H., Janols, H., Wullt, M., Bredberg, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127028 · Cited by 152
Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs
Porta, C., Consonni, F. M., Morlacchi, S., Sangaletti, S., Bleve, A., Totaro, M. G., Larghi, P., Rimoldi, M., Tripodo, C., Strauss, L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2843 · Cited by 152
Al-Khami, A. A., Hossain, F., Wyczechowska, D., Hernandez, C., Zheng, L., Reiss, K., Del Valle, L., Trillo-Tinoco, J., Maj, T., Zou, W., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-o18 · Cited by 150
Si, Y., Merz, S. F., Jansen, P., Wang, B.-X., Bruderek, K., Altenhoff, P., Mattheis, S., Lang, S., Gunzer, M., Klode, J., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aaw9159 · Cited by 150
Lathers, D. M. R., Clark, J. I., Achille, N. J., & Young, M. R. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0459-7 · Cited by 149
Raychaudhuri, B., Rayman, P. A., Huang, P., Grabowski, M. M., Hambardzumyan, D., Finke, J. H., & Vogelbaum, M. A. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1720-6 · Cited by 148
Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells
Wang, Z., Till, B., & Gao, Q. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1331807 · Cited by 145
Holtzhausen, A., Harris, W. P., Ubil, E., Hunter, D. M., Zhao, J., Zhang, Y., Zhang, D., Liu, Q., Wang, X., Graham, D. K., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0008 · Cited by 145
Hou, A., Hou, K., Huang, Q., Lei, Y., & Chen, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00783 · Cited by 145
de Coaña, Y. P., Poschke, I., Gentilcore, G., Mao, Y., Nyström, M., Hansson, J., Masucci, G. V., & Kiessling, R. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0016 · Cited by 140
Gutschalk, C. M., Herold‐Mende, C. C., Fusenig, N. E., & Mueller, M. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0158 · Cited by 139
Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines
Poschke, I. C., Mao, Y., Adamson, L., Salazar‐Onfray, F., Masucci, G. V., & Kiessling, R. W. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1143-y · Cited by 139
Takeuchi, S., Baghdadi, M., Tsuchikawa, T., Wada, H., Nakamura, T., Abe, H., Nakanishi, S., Usui, Y., Higuchi, K., Takahashi, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2921 · Cited by 138
Li, F., Zhao, Y., Wei, L., Li, S., & Liu, J. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1450116 · Cited by 138
CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy
Ma, Y., Mattarollo, S. R., Adjemian, S., Yang, H., Aymeric, L., Hannani, D., Portela Catani, J. P., Duret, H., Teng, M. W. L., Kepp, O., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1265 · Cited by 137
Self-citationRodríguez-Ubreva, J., Català-Moll, F., Obermajer, N., Álvarez-Errico, D., Ramirez, R. N., Company, C., Vento-Tormo, R., Moreno-Bueno, G., Edwards, R. P., Mortazavi, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.018 · Cited by 134
In vivo suppressive function of myeloid‐derived suppressor cells is limited to the inflammatory site
Haverkamp, J. M., Crist, S. A., Elzey, B. D., Cimen, C., & Ratliff, T. L. (2011) · European Journal of Immunology · doi:10.1002/eji.201041069 · Cited by 133
Hellmann, M. D., Jänne, P. A., Opyrchal, M., Hafez, N., Raez, L. E., Gabrilovich, D. I., Wang, F., Trepel, J. B., Lee, M.-J., Yuno, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3305 · Cited by 133
STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells
Guha, P., Gardell, J., Darpolor, J. K., Cunetta, M., Lima, M., Miller, G., Espat, N. J., Junghans, R. P., & Katz, S. C. (2018) · Oncogene · doi:10.1038/s41388-018-0449-z · Cited by 132
Aggen, D. H., Ager, C. R., Obradović, A., Chowdhury, N., Ghasemzadeh, A., Mao, W., Chaimowitz, M. G., Bujanda, Z. A. L., Spina, C. S., Hawley, J. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1610 · Cited by 132
Sharma, B., Nawandar, D. M., Nannuru, K. C., Varney, M. L., & Singh, R. K. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0529 · Cited by 131
Peereboom, D. M., Alban, T. J., Grabowski, M. M., Alvarado, A. G., Otvos, B., Bayık, D., Roversi, G. A., McGraw, M., Huang, P., Mohammadi, A. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130748 · Cited by 127
Markowitz, J., Brooks, T. R., Duggan, M. C., Paul, B. K., Pan, X., Wei, L., Abrams, Z., Luedke, E., Lesinski, G. B., Mundy-Bosse, B., et al. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1618-8 · Cited by 126
Chow, L. Q. M., Morishima, C., Eaton, K. D., Baik, C. S., Goulart, B. H., Anderson, L. N., Manjarrez, K. L., Dietsch, G. N., Bryan, J. K., Hershberg, R. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1934 · Cited by 126
Arrieta, O., González-De la Rosa, C. H., Aréchaga-Ocampo, E., Villanueva-Rodríguez, G., Cerón-Lizárraga, T. L., Martínez-Barrera, L., Vázquez-Manríquez, M. E., Ríos-Trejo, M. Á., Álvarez-Avitia, M. Á., Hernández-Pedro, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6452 · Cited by 125
Dutta, P., Sarkissyan, M., Paico, K., Wu, Y., & Vadgama, J. V. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4760-8 · Cited by 124
Draghiciu, O., Nijman, H. W., Hoogeboom, B. N., Meijerhof, T., & Daemen, T. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.989764 · Cited by 123
Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5
Wang, Y., Schafer, C. C., Hough, K. P., Tousif, S., Duncan, S. R., Kearney, J. F., Ponnazhagan, S., Hsu, H., & Deshane, J. S. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701069 · Cited by 122
Self-citationmTOR masters monocytic myeloid-derived suppressor cells in mice with allografts or tumors
Wu, T., Zhao, Y., Wang, H., Li, Y., Shao, L., Wang, R., Lu, J., Yang, Z., Wang, J., & Zhao, Y. X. (2016) · Scientific Reports · doi:10.1038/srep20250 · Cited by 121
A RIPK3-PGE2 Circuit Mediates Myeloid-Derived Suppressor Cell–Potentiated Colorectal Carcinogenesis
Yan, G., Zhao, H., Zhang, Q., Zhou, Y. J., Wu, L., Lei, J., Wang, X., Zhang, J., Zhang, X., Zheng, L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3962 · Cited by 121
Albeituni, S., Ding, C., Liu, M., Hu, X., Luo, F., Kloecker, G. H., Bousamra, M., Zhang, H., & Yan, J. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501853 · Cited by 120
Ku, A. W., Muhitch, J. B., Powers, C. A., Diehl, M. R., Kim, M., Fisher, D. T., Sharda, A. P., Clements, V. K., O’Loughlin, K. L., Minderman, H., et al. (2016) · eLife · doi:10.7554/elife.17375 · Cited by 120
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01795-9 · Cited by 120
The multifaceted role of TRAIL signaling in cancer and immunity
Alves, L. C., Corazza, N., Micheau, O., & Krebs, P. (2020) · FEBS Journal · doi:10.1111/febs.15637 · Cited by 120
Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation
Zhang, C.-X., Huang, D.-J., Baloche, V. M. D., Zhang, L., Xu, J.-X., Li, B., Zhao, X., He, J., Mai, H., Chen, Q., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-00248-0 · Cited by 117
Hou, W., Sampath, P., Rojas, J. J., & Thorne, S. H. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.012 · Cited by 115
Regulation of myelopoiesis by proinflammatory cytokines in infectious diseases
Chiba, Y., Mizoguchi, I., Hasegawa, H., Ohashi, M., Orii, N., Nagai, T., Sugahara, M., Miyamoto, Y., Xu, M., Owaki, T., et al. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2724-5 · Cited by 113
Montero, A. J., Diaz-Montero, C. M., Deutsch, Y. E., Hurley, J., Koniaris, L. G., Rumboldt, T., Yasir, S., Jorda, M., Garret-Mayer, E., Avisar, E., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1889-0 · Cited by 112
Li, W., Zhang, X., Chen, Y., Xie, Y., Liu, J., Feng, Q., Wang, Y., Yuan, W., & Ma, J. (2016) · Protein & Cell · doi:10.1007/s13238-015-0237-2 · Cited by 112
Self-citationKosaka, A., Ohkuri, T., & Okada, H. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1561-8 · Cited by 111
Cimen Bozkus, C., Elzey, B. D., Crist, S. A., Ellies, L. G., & Ratliff, T. L. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500959 · Cited by 111
Myeloid-Derived Suppressor Cell Survival and Function Are Regulated by the Transcription Factor Nrf2
Beury, D. W., Carter, K. A., Nelson, C., Sinha, P., Hanson, E., Nyandjo, M., Fitzgerald, P. J., Majeed, A., Wali, N., & Ostrand-Rosenberg, S. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501785 · Cited by 111
Myeloid-Derived Suppressor Cells in the Development of Lung Cancer
Ortiz, M. L., Lu, L., Ramachandran, I., & Gabrilovich, D. I. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0129 · Cited by 110
Koinis, F., Vetsika, E., Aggouraki, D., Skalidaki, E., Koutoulaki, A., Gkioulmpasani, M., Georgoulias, V., & Kotsakis, A. P. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.026 · Cited by 108
Chen, H.-M., Ma, G., Gildener‐Leapman, N., Eisenstein, S. G., Coakley, B. A., Ozao, J. J., Mandeli, J., Divino, C. M., Schwartz, M., Sung, M. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2742 · Cited by 106
Shi, H., Zhang, J., Han, X., Li, H., Xie, M., Sun, Y., Liu, W., Ba, X., & Zeng, X. (2016) · International Journal of Cancer · doi:10.1002/ijc.30538 · Cited by 106
Self-citationHassel, J. C., Jiang, H., Bender, C., Winkler, J. K., Sevko, A., Shevchenko, I., Halama, N., Dimitrakopoulou‐Strauss, A., Haefeli, W. E., Jäger, D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1326440 · Cited by 106
Sternberg, C., Armstrong, A., Pili, R., Ng, S., Huddart, R., Agarwal, N., Khvorostenko, D., Lyulko, O., Brize, A., Vogelzang, N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9697 · Cited by 105
Schouppe, E., Mommer, C., Movahedi, K., Laoui, D., Morias, Y., Gysemans, C., Luyckx, A., De Baetselier, P., & Van Ginderachter, J. A. (2013) · European Journal of Immunology · doi:10.1002/eji.201343349 · Cited by 104
Shen, M., Wang, J., Yu, W., Zhang, C., Liu, M., Wang, K., Yang, L., Wei, F., Wang, S. E., Sun, Q., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1413520 · Cited by 104
Gehad, A. E., Lichtman, M. K., Schmults, C. D., Teague, J. E., Calarese, A. W., Jiang, Y., Watanabe, R., & Clark, R. A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.190 · Cited by 103
Oseroff, A. R., Okada, S., & Strober, S. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.3.1585.b · Cited by 103
Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence
Ricciuti, B., Leonardi, G. C., Puccetti, P., Fallarino, F., Bianconi, V., Sahebkar, A., Baglivo, S., Chiari, R., & Pirro, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.004 · Cited by 102
Isambert, N., Hervieu, A., Rébé, C., Hennequin, A., Borg, C., Zanetta, S., Chevriaux, A., Richard, C., Dérangère, V., Limagne, E., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1474319 · Cited by 101
Steinberg, S. M., Shabaneh, T. B., Zhang, P., Martyanov, V., Li, Z., Malik, B. T., Wood, T. A., Boni, A., Molodtsov, A., Angeles, C. V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1755 · Cited by 100
Li, H., Ding, J., Lu, M., Liu, H., Miao, Y., Li, L., Wang, G., Zheng, J., Pei, D., & Zhang, Q. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000301 · Cited by 98
Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis
Qin, G., Lian, J., Huang, L. J., Zhao, Q., Liu, S., Zhang, Z., Chen, X., Yue, D., Li, L., Li, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1442167 · Cited by 96
Self-citationHorikawa, N., Abiko, K., Matsumura, N., Baba, T., Hamanishi, J., Yamaguchi, K. D., Murakami, R., Taki, M., Ukita, M., Hosoe, Y., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0725-x · Cited by 96
Myeloid Lineage–Specific Deletion of Antioxidant System Enhances Tumor Metastasis
Hiramoto, K., Satoh, H., Suzuki, T., Moriguchi, T., Pi, J., Shimosegawa, T., & Yamamoto, M. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0094 · Cited by 94
Negri, L., & Ferrara, N. (2018) · Physiological Reviews · doi:10.1152/physrev.00012.2017 · Cited by 93
Albu, D. I., Wang, Z., Huang, K.-C., Wu, J., Twine, N., Leacu, S., Ingersoll, C., Parent, L., Lee, W., Liu, D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338239 · Cited by 92
Oseroff, A. R., Okada, S., & Strober, S. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.1.101 · Cited by 92
for the “Working Group” of Systemic Autoinflammatory Diseases of SIR (Italian Society of Rheumatology), Sota, J., Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., Cattalini, M., Manna, R., Cimaz, R., et al. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4119-x · Cited by 90
Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment
Gonzalez-Junca, A., Driscoll, K. E., Pellicciotta, I., Du, S., Lo, C. H., Roy, R., Parry, R., Tenvooren, I., Marquez, D. M., Spitzer, M. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0310 · Cited by 89
Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells
Di, S., Zhou, M., Pan, Z., Sun, R., Chen, M., Jiang, H., Shi, B., Luo, H., & Li, Z. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00241 · Cited by 85
George, S., Rini, B. I., & Hammers, H. J. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4604 · Cited by 84
Karin, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.557586 · Cited by 84
Lee, M., Park, C., Lee, Y.-R., Im, S., Song, S., & Lee, C. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-014-0379-4 · Cited by 82
Shayan, G., Kansy, B. A., Gibson, S. P., Srivastava, R. M., Bryan, J. K., Bauman, J. E., Ohr, J., Kim, S., Duvvuri, U., Clump, D. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0357 · Cited by 82
Moreira, D., Adamus, T., Zhao, X., Su, Y.-L., Zhang, Z., White, S. V., Swiderski, P., Lu, X., DePinho, R. A., Pal, S. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1277 · Cited by 80
Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells
Younos, I., Donkor, M. K., Hoke, T. A., Dafferner, A. J., Samson, H., Westphal, S. N., & Talmadge, J. E. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.02.021 · Cited by 79
TIPE2 specifies the functional polarization of myeloid-derived suppressor cells during tumorigenesis
Yan, D., Wang, J., Sun, H., Zamani, A., Zhang, H., Chen, W., Tang, A., Ruan, Q., Yang, X., Chen, Y. H., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182005 · Cited by 78
Self-citationCresswell, G. M., Wang, B., Kischuk, E. M., Broman, M. M., Alfar, R. A., Vickman, R. E., Dimitrov, D. S., Kularatne, S. A., Sundaram, C. P., Singhal, S. K., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1414 · Cited by 77
Wang, J., Hu, W., Wang, K., Yu, J., Luo, B., Luo, G., Wang, W., Wang, H., Li, J., & Wen, J. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3371 · Cited by 75
Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2
Rong, Y., Yuan, C.-H., Qu, Z., Zhou, H., Guan, Q., Yang, N., Leng, X., Bu, L., Wu, K., & Wang, F.-B. (2016) · Scientific Reports · doi:10.1038/srep23824 · Cited by 74
Sayed, M. F. A., Amrein, M. A., Bührer, E. D., Huguenin, A.-L., Radpour, R., Riether, C., & Ochsenbein, A. F. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3026 · Cited by 74
Maenhout, S. K., Van Lint, S., Emeagi, P. U., Thielemans, K., & Aerts, J. L. (2014) · International Journal of Cancer · doi:10.1002/ijc.28449 · Cited by 73
Extracellular adenosine metabolism in immune cells in melanoma
Umansky, V., Shevchenko, I., Bazhin, A. V., & Utikal, J. S. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1553-8 · Cited by 73
Lü, P., Yu, B., & Xu, J. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1219 · Cited by 73
Seitz, L. C., Jin, L., Leleti, M. R., Ashok, D., Jeffrey, J. L., Rieger, A., Tiessen, R. G., Arold, G., Tan, J. B. L., Powers, J. P., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0706-6 · Cited by 72
Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs
Tannenbaum, C. S., Rayman, P. A., Pavicic, P. G., Kim, J. S., Wei, W., Polefko, A., Wallace, W., Rini, B. I., Morris‐Stiff, G. J., Allende, D. S., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0578 · Cited by 70
Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action
Take, Y., Koizumi, S., & Nagahisa, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00324 · Cited by 70
Chornoguz, O., Grmai, L., Sinha, P., Artemenko, K. A., Zubarev, R. A., & Ostrand-Rosenberg, S. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.002980 · Cited by 69
Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer
Al-Khami, A. A., Rodríguez, P. C., & Ochoa, A. C. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1200771 · Cited by 68
Hu, X., Bardhan, K., Paschall, A. V., Yang, D., Waller, J. L., Park, M. A., Nayak-Kapoor, A., Samuel, T. A., Abrams, S. I., & Liu, K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.434530 · Cited by 67
Eksioglu, E. A., Chen, X., Heider, K.-H., Rueter, B., McGraw, K. L., Basiorka, A. A., Wei, M., Burnette, A., Cheng, P., Lancet, J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.21 · Cited by 66
Shao, Y., Zhu, W., Da, J., Xu, M., Wang, Y., Zhou, J., & Wang, Z. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s130653 · Cited by 62
Self-citationDeng, Y., Yang, J., Luo, F., Qian, J., Liu, R., Zhang, D., Yu, H., & Chu, Y. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2177-1 · Cited by 62
Kinoshita, R., Sato, H., 山内, 明., Takahashi, Y., Inoue, Y., Sumardika, I. W., Chen, Y., Tomonobu, N., Araki, K., Shien, K., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31982 · Cited by 62
Self-citationMasuda, T., Noda, M., Kogawa, T., Kitagawa, D., Hayashi, N., Jomori, T., Nakanishi, Y., Nakayama, K. I., Ohno, S., & Mimori, K. (2020) · Cancer Science · doi:10.1111/cas.14306 · Cited by 62
Xu, P., Yin, K., Tang, X., Tian, J., Zhang, Y., Ma, J., Xu, H., Xu, Q., & Wang, S. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109458 · Cited by 61
Fleet, J. C., Burcham, G. N., Calvert, R. D., Elzey, B. D., & Ratliff, T. L. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105557 · Cited by 61
Gunaydin, G., Kesikli, S. A., & Guc, D. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1034918 · Cited by 59
Armstrong, A. J., Häggman, M., Stadler, W. M., Gingrich, J. R., Assikis, V. J., Polikoff, J. A., Damber, J. ‐., Belkoff, L. H., Nordle, Ö., Forsberg, G., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1581 · Cited by 57
Dumont, A., de Rosny, C., Kieu, T., Perrey, S., Berger, H., Fluckiger, A., Muller, T., de Barros, J.-P. P., Pichon, L., Hichami, A., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1723-x · Cited by 56
Tuyaerts, S., Rombauts, K., Everaert, T., Nuffel, A. M. T. V., & Amant, F. C. (2019) · Frontiers in Nutrition · doi:10.3389/fnut.2018.00138 · Cited by 55
Trillo-Tinoco, J., Sierra, R. A., Mohamed, E. T., Cao, Y. W., Pulido, Á. D. M., Gilvary, D. L., Anadon, C. M., Costich, T. L., Wei, S., Flores, E. R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0880 · Cited by 55
Hashimoto, A., Fukumoto, T., Zhang, R., & Gabrilovich, D. I. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02588-7 · Cited by 54
Wong, J. W., Tran, L. T., Magun, E. A., Magun, B. E., & Wood, L. J. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29922 · Cited by 52
Mariotti, V., Han, H., Ismail-Khan, R., Tang, S.-C., Dillon, P., Montero, A. J., Poklepovic, A., Melin, S., Ibrahim, N. K., Kennedy, E., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.5572 · Cited by 51
Domankevich, V., Cohen, A., Efrati, M., Schmidt, M. T., Rammensee, H., Nair, S. S., Tewari, A. K., Kelson, I., & Keisari, Y. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02418-5 · Cited by 50
Tumor regulation of myeloid-derived suppressor cell proliferation and trafficking
Younos, I., Dafferner, A. J., Gülen, D., Britton, H. C., & Talmadge, J. E. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.05.002 · Cited by 49
Coloma, C. S., Santaballa, A., Sanmartín, E., Calvo, D. C., García, A., Hervás, D., Cordón, L., Quintás‐Cardama, A., Ripoll, F., Panadero, J., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.08.020 · Cited by 49
Hajek, E., Krebs, F. K., Bent, R., Haas, K., Bast, A., Steinmetz, I., Tuettenberg, A., Grabbe, S., & Bros, M. (2018) · Oncotarget · doi:10.18632/oncotarget.25511 · Cited by 48
The immunoregulatory role of bone marrow
Duwe, A. K., & Singhal, S. K. (1979) · Cellular Immunology · doi:10.1016/0008-8749(79)90180-1 · Cited by 47
Forghani, P., & Waller, E. K. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3508-y · Cited by 46
Khan, A. N. H., Emmons, T. R., Wong, J. T., Alqassim, E., Singel, K. L., Mark, J., Smith, B. E., Tario, J. D., Eng, K. H., Moysich, K. B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0556 · Cited by 46
Ding, Z., Munn, D. H., & Zhou, G. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954471 · Cited by 42
Shime, H., Kojima, A., Maruyama, A., Saito, Y., Oshiumi, H., Matsumoto, M., & Seya, T. (2013) · Journal of Innate Immunity · doi:10.1159/000355126 · Cited by 42
Matsushita, H., Enomoto, Y., Kume, H., Nakagawa, T., Fukuhara, H., Suzuki, M., Fujimura, T., Homma, Y., & Kakimi, K. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0030-4 · Cited by 42
Zhou, J., Donatelli, S. S., Gilvary, D. L., Tejera, M. M., Eksioglu, E. A., Chen, X., Coppola, D., Sheng, W., & Djeu, J. Y. (2016) · Scientific Reports · doi:10.1038/srep29521 · Cited by 40
Diaz-Montero, C. M., Wang, Y., Shao, L., Feng, W., Zidan, A. A., Pazoles, C. J., Montero, A. J., & Zhou, D. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.007 · Cited by 39
Self-citationA STUDY OF THE LEUKEMOID RESPONSE TO TRANSPLANTABLE A-280 TUMOR IN MICE.
LAPPAT, E. J., & Cawein, M. (1964) · PubMed · Cited by 38
Bian, Z., Shi, L., Venkataramani, M., Abdelaal, A. M., Culpepper, C. D., Kidder, K., Liang, H., Zen, K., & Liu, Y. (2017) · European Journal of Immunology · doi:10.1002/eji.201746976 · Cited by 38
Lee, M. Y., & Rosse, C. (1982) · PubMed · Cited by 36
Orally administered CCR2 selective inhibitor CCX872-b clinical trial in pancreatic cancer.
Noel, M. S., Hezel, A. F., Linehan, D. C., Wang‐Gillam, A., Eskens, F. A. L. M., Sleijfer, S., Desar, I. M. E., Erdkamp, F., Wilmink, J. W., Diehl, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.276 · Cited by 36
Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer
Пили, Р., Ustwani, O. A., Gupta, N., & Shen, L. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s53524 · Cited by 35
Curdlan blocks the immune suppression by myeloid-derived suppressor cells and reduces tumor burden
Rui, K., Tian, J., Tang, X., Ma, J., Xu, P., Tian, X., Wang, Y., Xu, H., Lu, L., & Wang, S. (2016) · Immunologic Research · doi:10.1007/s12026-016-8789-7 · Cited by 35
Self-citationStimulation of immune-suppressive bone marrow cells by colony-stimulating factors.
Young, M. R., Young, M. E., & Wright, M. A. (1990) · PubMed · Cited by 33
Tian, X., Tian, J., Tang, X., Rui, K., Zhang, Y., Ma, J., Wang, Y., Xu, H., Lu, L., & Wang, S. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1038687 · Cited by 31
Self-citationSun, H.-W., Chen, J., Wu, W., Yang, Y., Xu, Y.-T., Yu, X.-J., Chen, H., Wang, Z., Wu, X., & Zheng, L. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0389 · Cited by 30
Tazzari, M., Negri, T., Rini, F., Vergani, B., Huber, V., Villa, A., Dagrada, G. P., Colombo, C., Fiore, M., Gronchi, A., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.437 · Cited by 29
Su, Y., Qiu, Y., Qiu, Z., & Qu, P. (2019) · Journal of Cancer · doi:10.7150/jca.35205 · Cited by 29
Escudier, B. J., Faivre, S. J., Cutsem, E. V., Germann, N., Pouget, J.-C., Plummer, R., Vergote, I. B., Thistlethwaite, F. C., Bjarnason, G. A., Jones, R. J., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0525-2 · Cited by 28
Effect of CpG ODN on monocytic myeloid derived suppressor cells
Shirota, H., & Klinman, D. M. (2012) · OncoImmunology · doi:10.4161/onci.19731 · Cited by 26
Tasquinimod targets suppressive myeloid cells in the tumor microenvironment
Shen, L., & Пили, Р. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1072672 · Cited by 25
Tumor-Induced Immune Suppression
Gabrilovich, D. I., & Hurwitz, A. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-69118-3 · Cited by 22
Blood-based analyses of cancer: Circulating myeloid-derived suppressor cells – is a new era coming?
Okła, K., Wertel, I., Wawruszak, A., Bobiński, M. S., & Kotarski, J. (2018) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2018.1477729 · Cited by 20
LXR Agonism Depletes MDSCs to Promote Antitumor Immunity
(2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2018-010 · Cited by 18
Tokunaga, R., Cao, S., Naseem, M., Lo, J. H., Battaglin, F., Puccini, A., Berger, M. D., Soni, S., Millstein, J., Zhang, W., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.09.003 · Cited by 17
Bennett, J. A., & Mitchell, M. S. (1979) · Biochemical Pharmacology · doi:10.1016/0006-2952(79)90649-x · Cited by 14
Functional Alteration of Tumor-infiltrating Myeloid Cells in RNA Adjuvant Therapy.
Seya, T., Shime, H., & Matsumoto, M. (2015) · PubMed · Cited by 10
NOV-002 plus carboplatin in platinum-resistant ovarian cancer
Krasner, C. N., Seiden, M. V., Penson, R. T., Roche, M. R., Kendall, D. L., Young, J., Matulonis, U. A., Pereira, L., & Berlin, S. T. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5593 · Cited by 9
Rodríguez, P. C., & Ochoa, A. C. (2014) · Springer eBooks · doi:10.1007/978-1-4899-8056-4_13 · Cited by 4
Cited by
Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies
Zhou, Q., Meng, Y., Li, D., Yao, L., Le, J., Liu, Y., Sun, Y., Zeng, F., Chen, X., & Deng, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01769-5 · Cited by 890
Self-citationCold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Self-citationRadiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Metadata
- Authors
- Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2021-10-07
- Volume
- 6
- Issue
- 1
- Pages
- 362-362
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W3202545704
- Cited by
- 988
- References
- 336
- FWCI
- 33.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.